{"id":"W3131487333","doi":"10.1016/j.msard.2021.102844","title":"Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program","year":2021,"lang":"en","type":"article","venue":"Multiple Sclerosis and Related Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; NeuroRx Research (Canada); Montreal Neurological Institute and Hospital","funders":"Sanofi Genzyme; Allergan; EMD Serono; MedDay Pharmaceuticals; Innosuisse - Schweizerische Agentur für Innovationsförderung; Schweizerische Multiple Sklerose Gesellschaft; Eisai; Alexion Pharmaceuticals; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Multiple Sclerosis Society; Ministerstvo Školství, Mládeže a Tělovýchovy; Atara Biotherapeutics; Mylan; Baxalta; TG Therapeutics; National Research Foundation; F. Hoffmann-La Roche; Novartis; Celgene; Bayer; Pfizer; Biogen; Roche; Teva Pharmaceutical Industries; Bayer HealthCare; European Commission; Multiple Sclerosis International Federation; Sanofi; Genentech; National Multiple Sclerosis Society; Merck; CSL Behring; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; MedDRA; Population; Adverse effect; Placebo; Clinical trial; Incidence (geometry); Phases of clinical research; Pathology; Pharmacovigilance","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01909509,0.0009843174,0.002429863,0.001206706,0.0002121237,0.0009950456,0.0006398799,0.0007663099,0.002419887],"category_scores_gemma":[0.01621519,0.0003637326,0.004844028,0.001496115,0.000406091,0.0006836982,0.0008834595,0.0008552901,0.0003331098],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005885763,"about_ca_system_score_gemma":0.001098342,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005637019,"about_ca_topic_score_gemma":0.0008767391,"domain_scores_codex":[0.9922218,0.004796702,0.0008866062,0.0007319774,0.00115158,0.0002113353],"domain_scores_gemma":[0.9886827,0.004031113,0.004923556,0.0008475611,0.001157199,0.0003577956],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.5428771,0.001595944,0.07101963,0.009531872,0.1072272,0.0002194389,0.0002574223,0.004331073,0.006856158,0.0002256315,0.005896416,0.2499623],"study_design_scores_gemma":[0.258577,0.1024253,0.4222514,0.001393071,0.1853104,0.001181256,0.000196907,0.004614151,0.006705766,0.0008917931,0.01627018,0.0001827283],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8936208,0.08293091,0.005181978,0.0007602344,0.0001573498,0.002914971,0.01008387,0.0002364489,0.004113327],"genre_scores_gemma":[0.9750271,0.01367798,0.002199438,0.0004699271,0.0002455202,0.001110816,0.00656571,0.00004366658,0.0006597321],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01909509,"threshold_uncertainty_score":0.1009857,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08706421045346827,"score_gpt":0.316655371971675,"score_spread":0.2295911615182067,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}